In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. - Wikidata - awgldk - TriplyDB

In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.

In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.

http://www.wikidata.org/entity/Q42031262

about

Kinetics of avibactam inhibition against Class A, C, and D β-lactamases Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria Three decades of beta-lactamase inhibitors The β-Lactams Strike Back: Ceftazidime-Avibactam Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC -Lactamases NXL104 Irreversibly Inhibits the β-Lactamase from Mycobacterium tuberculosis Investigations on recyclisation and hydrolysis in avibactam mediated serine β-lactamase inhibition Emergence and dissemination of multi-resistant Gram negative Enterobacteriaceae: lessons to be learnt from local and national surveillance programs in Belgium.New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Postgenomic strategies in antibacterial drug discovery.Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.Antibiotic discovery in the twenty-first century: current trends and future perspectives.Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens The enzymes of β-lactam biosynthesis.Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.Investigational antimicrobial agents of 2013.Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model.In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.Ecological Effect of Ceftaroline-Avibactam on the Normal Human Intestinal Microbiota Interaction between gentamicin and mycophenolate mofetil in experimentally induced pyelonephritis Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).Identification of the β-lactamase inhibitor protein-II (BLIP-II) interface residues essential for binding affinity and specificity for class A β-lactamases Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China.New definitions of extended-spectrum β-lactamase conferring worldwide emerging antibiotic resistance.Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns.Development of new drugs for an old target: the penicillin binding proteins.β-Lactamase inhibitors: a review of the patent literature (2010 - 2013).Confronting carbapenemase-producing Klebsiella pneumoniae.Drug repurposing screens and synergistic drug-combinations for infectious diseases.

P2860

Q24617763-9F0269A8-19F6-40BC-AEB4-A19FA6038871 Q24618178-2B1A90C7-DE6C-4AE4-8324-7F28C0E74870 Q24646623-3FC164D1-D206-476A-AF38-7E856FA5066C Q26796425-6B56F815-8998-4848-9DF5-55AACD0151A8 Q26995305-AB4CEB78-7B47-41E4-8BA3-5B96D876CCC2 Q27676626-27E2A970-CF2F-4E7D-8BC6-582AF72038F3 Q27679097-AD2A9CF5-BA9E-4782-9F3B-E61C916629B2 Q28834096-31D5ACAA-0994-46B8-B72F-EAC1CC212341 Q30368402-F875994C-38A4-4DA9-9B54-29E123E376F1 Q33622976-FB554A0B-45DF-4A90-AC8B-34C227FD1B62 Q33745572-5B185906-2F82-4565-978D-94FA45CBCCDE Q34058217-D805F5F7-F8FF-4CDA-B518-96321401294E Q34109281-F0ECB429-A1D0-493A-AB23-D36E9F587827 Q34121033-8165F3CB-F0F4-4C7C-9751-37754FD565D3 Q34303970-54BE0289-DDDD-403F-9485-7C83C47ED3CE Q34310470-76CD5350-F233-4BAC-8F65-E5CB83E3E0BA Q34325573-9761D5A8-E845-4C3E-AF98-D2D6F6178301 Q34375204-0FCCD773-B008-43F5-9780-C51FAA535AFD Q34402134-95FD219A-F0DD-4314-BE3D-7EDDBBEAA6E2 Q34483491-F66DA5F8-5198-4534-9EAC-5CBFEF41B87B Q34596516-2F6A2C33-EC29-4671-AC3C-7FADF03BCD47 Q34596918-FF789A31-2280-49A1-815A-03271B18F8F1 Q35065798-BC7F9E6D-36F3-4052-9E93-C2F78DE4023F Q35634838-F25CCEE9-82D0-441D-81E2-8E1A4EEC53C7 Q35685988-D5D599A4-A43D-40BD-AE85-2377332FAC51 Q36201543-27C87F93-EB18-45AF-9A2B-D4F7EEA309B6 Q36361921-4EB48575-683A-4BA0-8052-D67F9FC74F07 Q36571851-D7AA7A95-75B5-4DCF-9DD6-4F9518F06353 Q36644679-21C144F8-02CD-4B5A-9C7F-56A8F60C1FD0 Q36667104-F068E10B-7A54-4167-A681-77B8B6BC5E78 Q36888062-6C89F198-76CB-4BEB-8146-D6A64F2AB48D Q36928945-959D32ED-0381-4D17-A6F6-A2D89499473F Q37055016-26DB0794-34C1-49BC-8CD0-0EE2C55BA135 Q37643595-46903E7B-FF2C-448C-915C-F2ECC246BB8A Q37767653-0AA82A8D-3CC0-4DFE-A69B-3CA11B192A3D Q38001333-D4531B20-0AB3-4048-BA51-C40DC49A97C6 Q38055325-51174275-4152-4CE9-8BBA-5BDEA82891B4 Q38130715-BF6380DE-831E-47A7-86D6-85C98BC7EE55 Q38135903-DE32E413-C59F-4533-9FB9-210D75ADC64E Q38158092-BB0AB0C0-E9E7-44ED-BE65-0226C7E667C6

P2860

In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.

http://www.wikidata.org/entity/Q42031262

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

In vitro activity of the {beta ...... expressing KPC carbapenemases.

@en

In vitro activity of the {beta ...... expressing KPC carbapenemases.

@nl

type

label

In vitro activity of the {beta ...... expressing KPC carbapenemases.

@en

In vitro activity of the {beta ...... expressing KPC carbapenemases.

@nl

prefLabel

In vitro activity of the {beta ...... expressing KPC carbapenemases.

@en

In vitro activity of the {beta ...... expressing KPC carbapenemases.

@nl

P1433

Q42031262-B79CE54B-E4B3-413C-B304-07B06497EA92

P1476

Q42031262-F4DC7101-5DBE-4AF0-A62A-D5F90DB54782

P2093

Q42031262-05AF1F85-EC2F-4B1A-A140-5D89D4C9C34F

Q42031262-215EC539-5A8D-46EF-9A2E-E71952B3FB9B

Q42031262-6A2D81B8-4E3B-408F-9CD6-8A4CBF922085

Q42031262-A642A593-CB6A-47EE-A06D-9E2DB7859806

Q42031262-D284011F-B0CF-41F7-9DDD-A7556EBC14BE

Q42031262-F5E83454-A93E-4D07-A4D9-D29EF5614731

Q42031262-FC222FE3-79FF-4415-91EA-AD354D38E773

P2860

Q42031262-016C42FD-9C53-4043-BCE4-39BFA8871F4C

Q42031262-01F0A457-4758-49AD-B96F-913A3BD92E21

Q42031262-17B03DFA-555B-4819-AB3B-67DEA4C385C1

Q42031262-25090615-80A6-42DB-8BF1-39B00E74FE2F

Q42031262-395A8CFF-CFCF-46A2-A0C5-94F964E456CE

Q42031262-4CD42EA6-0E2C-4504-B6F1-D5E92253C255

Q42031262-517BD7C2-BC15-44C4-B032-52BB950A9B78

Q42031262-535575C5-8B77-426D-8FE6-A422B3CF7DF7

Q42031262-5C2A2E93-A814-45F5-9A0D-3E1F18085842

Q42031262-5DF6DED8-FB68-466C-899A-246F07218515

P304

Q42031262-40D2A9C6-34B8-4F45-955C-3F80AA1E2383

P31

Q42031262-AF82B5D9-30A1-40B0-8259-D70B41E7E8BA

P356

Q42031262-899B694E-55D8-49F9-AFC5-5E334A35E395

P407

Q42031262-4D93BDA7-8549-43C8-AD46-46571903DF42

P433

Q42031262-AC36D57D-E626-4503-95C1-FCB093EF7C30

P478

Q42031262-C48C49EE-A373-4D19-A592-D33522B8BBC5

P577

Q42031262-79A9F03D-79E8-42E1-AB97-5E355EF1A256

P5875

Q42031262-CAD31B19-4AA7-419C-9F9D-1F50FEFBD7BE

P698

Q42031262-600009AA-6E6A-4FDC-B75E-B60AE50431C7

P932

Q42031262-93D1F6E6-599C-4979-ADBB-B8C1F527C513

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

In vitro activity of the {beta ...... expressing KPC carbapenemases.

@en

P2093

Anne-Marie Girard

http://www.w3.org/2001/XMLSchema#string

Christine Miossec

http://www.w3.org/2001/XMLSchema#string

Marie-Claude Péchereau

http://www.w3.org/2001/XMLSchema#string

Michael T Black

http://www.w3.org/2001/XMLSchema#string

Monique Claudon

http://www.w3.org/2001/XMLSchema#string

Premavathy Levasseur

http://www.w3.org/2001/XMLSchema#string

Thérèse Stachyra

http://www.w3.org/2001/XMLSchema#string

P2860

Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae

Genetic and Structural Insights into the Dissemination Potential of the Extremely Broad-Spectrum Class A -Lactamase KPC-2 Identified in an Escherichia coli Strain and an Enterobacter cloacae Strain Isolated from the Same Patient in France

Redefining penems

Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.

First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America.

The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril!

Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes.

Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.

Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases

Identification of carbapenem-resistant klebsiella pneumoniae harboring KPC enzymes in New Jersey.

P304

326-329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKP197

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26264300

http://www.w3.org/2001/XMLSchema#string

P698

19493866

http://www.w3.org/2001/XMLSchema#string

P932

2707266

http://www.w3.org/2001/XMLSchema#string